Key benefits of a microfluidic platform for cell culture at a clinically relevant scale

Cell & Gene Therapy Insights 2022; 8(8), 1021;

DOI: 10.18609/cgti.2022.151

Published: 10 September 2022
James Kusena, Mohsen Shaeri, Pedro Costa

Watch the video or read the poster to learn:

  • The capabilities of an automated cell therapy workstation for process development and manufacturing combining advanced end-to-end bioprocessing and analytical capabilities and seamless scale-up/down
  • Highly efficient bioprocessing of primary T-cells, with 5-10x lower viral vector consumption, higher fold expansion, and tighter control of cell phenotype compared to conventional research cell culture vessels
  • Bioprocessing of adherent mesenchymal stem cells in monolayer in the MicrofluidX platform, which has been shown to surpass the performance of conventional cell culture vessels with a 3x higher cell density while maintaining cell phenotype
  • Longitudinal studies over 6 passages of mesenchymal stem cells, which showed 50% higher average and 30% lower variability in cell densities compared to flask culture, while maintaining cell phenotype across all passages

James Kusena is the VP Bioprocessing and Applications at MicrofluidX. James holds a PhD in human pluripotent stem cell culture and differentiation from Loughborough University, UK. He has 6 years of experience in cell therapy process development and manufacturing optimization. His background is in medicinal chemistry, international business and health economics

Mohsen Shaeri is a Senior Scientist at the Cell and Gene Therapy Catapult, specializing in process development. He has 4 years of experience in microfluidic cell culture and over 12 years of experience in bioprocessing and automation, with a focus on cell therapies. He holds a PhD in Bioengineering from the University of Sheffield, UK.

Pedro Costa is the Head of Operations at Stemmatters. Pedro holds a degree in Biochemistry from the University of Coimbra (Portugal) and a PhD in Biochemistry from the University of Coimbra in co-operation with Columbia University (NY, USA). He has over six years of experience in biomedical research, with a particular focus on nanocarrier development and functionalization, and in primary cell and stem cell isolation/culture, cell-based assays, and genome editing.